Device to be used with Merial's Melanoma Vaccine for Dogs
PORTLAND, Ore., March 26 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that it has developed a canine melanoma
device for Merial Ltd. ("Merial"), a world leading animal health company,
for use with Merial's canine melanoma vaccine for dogs. Today, the USDA
approved the vaccine and Merial will be launching it with Bioject's
modified Vitajet(TM)3 spring-based device.
Bob Nordgren, Head of Research, Technology Acquisition and North
American Biological Development at Merial commented, "In studies conducted
at the Animal Medical Center, the combination vaccine and device showed
success in prolonging survival time in dogs with oral melanoma. We look
forward to providing the animal health market with the vaccine via
needle-free delivery."
"Once again we have shown an improved delivery system for the delivery
of a specific vaccine. We have worked many years with Merial and the Animal
Medical Center to improve the treatment and care for animals with
melanoma," said Dr. Richard Stout, Executive Vice President and Chief
Medical Officer.
"We are pleased to have delivered the melanoma device to Merial for use
with the vaccine," said Jerald S. Cobbs, Chairman, Interim President and
CEO of Bioject, "and we continue to look forward to offering Merial other
needle-free products. A similar DNA-based vaccine for humans using our
Biojector(R) 2000 device is currently in clinical trials."
Bioject and Merial, a joint venture between Merck & Co. and
sanofi-aventis, currently have collaborations for Bioject's Vetjet(TM)
product, which was commercialized in 2004, and its Derma-Vac(TM) NF device
for swine, which was recently commercialized.
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
For more information on Bioject, visit http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com/
CONTACT:
Jerald S. Cobbs, Chairman, Interim President
and CEO, +1-503-692-8001, ext. 4161, or Chris Farrell, Vice
President of Finance, +1-503-692-8001, or ext. 4132, both of
Bioject Medical Technologies Inc.
|
